This compound 3 is a lead chemical scaffold for the further development of lysine demethylase 6B (KDM6B
, also known as JMJD3 and Jumonji D3) inhibitors. JMJD3 is an inducible enzyme, that along with ubiquitously transcribed X chromosome tetratricopeptide repeat protein (UTX), forms the KDM6 subfamily of histone modifying enzymes, which catalyze the demethylation of lysine 27 on histone H3 (H3K27). H3K27 demethylases are involved in maintaining the epigenetic transcriptional state in replicating and postmitotic cells. Prior to the discovery of compound 3, GSK-J1
and its derivatives were the only selective KDM6 inhibitors to be reported [5-6
]. Compound 3 is suitable for investigating the role of JMJD3 in normal tissues and in tissues that are altered by pathological conditions, such as cancer and inflammation.